title: Plasma neuropeptide Y immunoreactivity influences left ventricular mass in pheochromocytoma.
abstract: Left ventricular hypertrophy (LVH) in patients with arterial hypertension is closely related to the levels of blood pressure (BP), catecholamines, angiotensin II and other mitogenic peptides. Pheochromocytoma (pheo) is a type of hypertension caused by excessive production of catecholamines. The aim of this study was to determinate if left ventricular hypertrophy in patients with pheochromocytoma is related to catecholamines and neuropeptide Y (NPY).
  
  
  METHODS
  29 patients with pheochromocytoma (22 F, age 40 +/- 13 years), plasma concentration of neuropeptide Y immunoreactivity, noradrenaline (NA), and adrenaline (A) were determined. Twenty-four hour urine collection for determination of noradrenaline and adrenaline were performed. Every patient had echocardiographic examination and 24 h ambulatory blood pressure monitoring.
  
  
  RESULTS
  Left ventricular hypertrophy was diagnosed in 14 patients. No differences in systolic and diastolic blood pressure in patients with and without left ventricular hypertrophy were found. Plasma noradrenaline and adrenaline levels did not differ between both groups, while plasma neuropeptide Y immunoreactivity was higher in patients with left ventricular hypertrophy than in patients without left ventricular hypertrophy (18.46 +/- 13.26 vs. 9.3 +/- 5.9 fmol/ml (p = 0.02)). Left ventricular mass index (LVMI) correlated with plasma neuropeptide Y-immunoreactivity (r = 0.42 p = 0.023), however, no relationship between left ventricular mass index and plasma or urine noradrenaline and adrenaline levels were found.
  
  
  CONCLUSIONS
  Our results indicate that mitogenic effect of neuropeptide Y may play a role in pathogenesis of left ventricular hypertrophy in patients with pheochromocytoma.
authors.affiliation: Department of Internal Medicine and Hypertension, The Medical University of Warsaw, Banacha 1a. 02-097 Warsaw, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Kuch-Wocial
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Slubowska
authors.forename: Maciej
authors.initials: M
authors.lastname: Kostrubiec
authors.forename: Tomasz
authors.initials: T
authors.lastname: Pasierski
authors.forename: Włodzimierz
authors.initials: W
authors.lastname: Januszewicz
authors.forename: Hanna
authors.initials: H
authors.lastname: Switalska
authors.forename: Bozena
authors.initials: B
authors.lastname: Wocial
authors.forename: Piotr
authors.initials: P
authors.lastname: Pruszczyk
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000097:blood* / Q000473:pathology* / Q000503:physiopathology; D000328:Adult; D001794:Blood Pressure / Q000502:physiology; D002395:Catecholamines / Q000097:blood; D004562:Electrocardiography; D004837:Epinephrine / Q000097:blood / Q000652:urine; D005260:Female; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000097:blood* / Q000473:pathology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009478:Neuropeptide Y / Q000097:blood* / Q000276:immunology; D009638:Norepinephrine / Q000097:blood / Q000652:urine; D010673:Pheochromocytoma / Q000097:blood* / Q000473:pathology* / Q000503:physiopathology
chemical_list: D002395:Catecholamines; D009478:Neuropeptide Y; D009638:Norepinephrine; D004837:Epinephrine